https://www.selleckchem.com/products/azd8186.html
Prior to matching, 30-day mortality was found to be 0.4% in the NAX cohort and 0.7% GA. 12,180 patients equally matched between the 2 groups. NAX was found to be superior to GA in terms of 30-day survival benefit(OR 0.55, 95% CI 0.33 -0.92, P 0.05), sepsis (OR 0.60, 95% CI 0.50 -0.73, P 0.001), and return to operating room (OR 0.76, 95% CI 0.60 -0.98, P 0.05) when comparing matched cohorts. NAX was associated with lower incidence of overall adverse clinical outcomes 12.4% vs 13.7% (P=0.036). NAX was found to have statistical
Like
Comment
Share
